PLK1 and acute myeloid leukemia: As a low-molecular-weight, ATP-competitive kinase inhibitor, BI6727 effectively inhibits PLK1, PLK2, and PLK3 and has shown promising effects in various xenograft models and patients with acute myeloid leukemia (AML) (Gjertsen and Schöffski, 2015).